Skip to main content

Fresenius Value Stock - Dividend - Research Selection

Fresenius SE & Co. KGaA

ISIN: DE0005785604 , WKN: 578560

Market price date: 12.06.2020
Market price: 42,22 EUR




Fresenius SE & Co. KGaA Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 24-02-2020
Cash flow
Net operating cash flow 4.263.000.000
Capital Expenditures -2.433.000.000
Free cash flow 1.830.000.000
Balance sheet
Total Equity 16.778.000.000
Liabilities & Shareholders equity 67.006.000.000
Income statement
Net income 1.883.000.000
Eps (diluted) 3,380
Diluted shares outstanding 557.101.000
Net sales/revenue 35.409.000.000

Fundamental ratios calculated on: 12-06-2020

Ratios
Key figures 12-06-2020
Cash flow
P/C 5,52
   
P/FC 12,85
Balance sheet
ROI2,81
ROE25,04
Income statement
P/E12,49
Div. Yield1,99%
P/B1,40
P/S0,66


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolFRE.XETRA
Market Capitalization27.032.299.520,00 USD
CountryGermany
IndicesDax,EURO STOXX 50
SectorsPharma
Raw Data SourceIFRS in Millionen EUR
Stock Split2014-08-04,3.0000/1.0000; 2007-02-02,3.0000/1.0000; 2005-11-17,2004.000000/1955.000000; 2001-06-11,2.000000/1.000000; 1995-12-11,10.000000/1.000000
Internetwww.fresenius.com


Description of the company

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.fresenius.com